Janssen Pharmaceuticals Inc Archives - Carey Danis & Lowe

Jury Awards Plaintiff in Topamax Case with $4 Million

By | Pharmaceutical litigation, Topamax, Uncategorized

topamax_birth_defects_topamax_during_pregnancy_topamax_lawsuit_settlements_cleft_lip_clefte_palateIn the latest Topamax lawsuit news, a jury in Philadelphia recently decided to award the plaintiff in a Topamax birth defects lawsuit with $4.02 million in damages. The case involves the plaintiff, April Czimmer, who claims that her son was born with an oral defect after she used Topamax, an anti-epileptic drug, during pregnancy. Czimmer’s case is the first lawsuit pertaining to the link between Topamax and congenital birth defects to go to trial.

Czimmer claims that the pharmaceutical company behind Topamax, Janssen Pharmaceuticals, failed to warn health care providers and patients about the high risk of children developing birth defects when exposed to the drug in the womb. The amount of the damages award clearly demonstrates that the jury finds Janssen Pharmaceuticals neglectful of patient health and safety.

Janssen Pharmaceuticals filed a request to block punitive damages in the case, which was granted by the court. Thus, the damages award reflects what the jury believes Czimmer and her son are due for their pain, suffering, and medical expenses, both past and future.

The case is Czimmer v. Janssen Pharmaceuticals Inc., which was being heard in the Court of Common Pleas in Philadelphia County, Pennsylvania.

There are another 134 cases pending in the Philadelphia court, according to Bloomberg. Carey Danis & Lowe Topamax attorneys are curious to see how the Czimmer case will impact future Topamax cases.

The U.S. Food and Drug Administration (FDA) released a safety announcement in March 2011 about the increased risk of children developing oral defects, such as a cleft lip or a cleft palate, when exposed to Topamax in the womb. It was at the time of this safety announcement that the FDA re-categorized Topamax as a Pregnancy D drug, meaning that there is human evidence showing a strong link between Topamax and oral defects.

How can Carey Danis & Lowe can help you and your child?

The Topamax attorneys at Carey Danis & Lowe work with victims of defective drugs and medical devices. We understand the harm these products can cause, which is why we are currently investigating Topamax cases. Carey Danis & Lowe is here to help you and your family, and welcomes you to contact our St. Louis based law firm for a free case evaluation.

Furthermore, if you would like to learn more about Topamax birth defects, speak with one of Carey Danis & Lowe’s on-staff medical experts, who can answer all of your questions on the matter.

Share your Topamax birth defects story with us today by calling 800.721.2519, or by completing one of our confidential personal injury claim forms.

Carey Danis & Lowe previously reported on the Czimmer case in October. Learn more about the Czimmer Topamax birth defects lawsuit on our personal injury litigation blog.

Topamax Birth Defects News: Lawsuit Claims Janssen Knew About Birth Defects Risk

By | Pharmaceutical litigation, Topamax, Uncategorized

topamax_birth_defects_topamax_during_pregnancy_topamax_lawsuit_settlements_cleft_lip_clefte_palateWomen are filing lawsuits against Janssen Pharmaceuticals, a unit of Johnson & Johnson, over their anti-epileptic medication Topamax. One such lawsuit is being heard in a Pennsylvania court, and involves the plaintiff, April Czimmer, whose son was born with oral defects.

Czimmer accuses Janssen of not warning users of Topamax birth defects risks prior to a 2011 order from the U.S. Food and Drug Administration (FDA).

The FDA sent out a safety announcement in March 2011 about the risk of oral clefts in children born to women using Topamax. They cited recent findings from human studies that strengthened the case of children developing oral defects when exposed to Topamax in the womb. As a result, the FDA categorized Topamax as a Pregnancy Category D drug.

Though the plaintiff’s primary argument in the Pennsylvania case involves Janssen’s lack of warning, the presiding judge in the case, Judge Arnold New, removed these claims from the litigation along with defective drug allegations. In addition, per Judge New’s approval, Janssen will not be targeted with punitive damages.

Instead, the trial’s updated focus involves company negligence, misleading marketing, and dishonest business practices.

Czimmer v. Janssen Pharmaceuticals Inc. is being heard in the Court of Common Pleas in Philadelphia County, Pennsylvania.

When pharmaceutical companies knowingly endanger lives through a lack of warning, Carey Danis & Lowe defective pharmaceutical attorneys strongly believe it is important to hold them accountable. In the case of Janssen, which many claim were aware of the birth defects risk well before the FDA safety alert in 2011, withholding such information is deceitful and compromises patient safety.

Carey Danis & Lowe assists individuals who claim that their child’s birth defects are due to Topamax exposure in the womb. Often, these women accuse Janssen of a failure to warn, misleading marketing, and company negligence. Though the Pennsylvania case has ruled out the failure to warn accusation, this is does not mean that every court hearing Topamax birth defects lawsuits will follow suit.

If your child was born with an oral defect after being exposed to Topamax in the womb, you and your child may be eligible for compensation. Discuss your Topamax case with a Carey Danis & Lowe Topamax attorney in a free legal consultation.

Share your story with Carey Danis & Lowe by calling 800.721.2519, or by completing a confidential personal injury claim form.